Sialic acid–guided spatiotemporal hydrogel therapy for liver cancer
Source abstract
Abstract
Efficient delivery of plant-derived polyphenolic drugs to tumor sites in hepatocellular carcinoma (HCC) is challenging due to their rapid metabolism and the limited tumor-targeting capacity of current therapeutic strategies. To overcome these limitations, we developed a pH-responsive hydrogel-based drug delivery system (PA-CB) composed of a chitosan backbone functionalized with boronobenzoic acid (CB) and crosslinked with protocatechualdehyde (PA). Within this scaffold, protocatechuic acid (PCA) was incorporated as a model therapeutic agent to demonstrate the platform's ability to achieve controlled, pH-responsive release and to impart anticancer, anti-inflammatory, and antifibrotic effects through the action of the drug. The hydrogel, stabilized via boronate ester and Schiff-base linkages, maintained integrity under physiological conditions while enabling drug markedly enhanced anticancer efficacy in vitro compared to free PCA, including a near-complete reduction of HepG2 cell viability, migration, and colony formation, along with increased apoptosis. This enhanced antitumor efficacy was due to CB-mediated recognition of sialic acid residues on HCC cells, which facilitated tumor-selective accumulation and sustained drug release. Intraperitoneal administration of the hydrogel in an HCC mouse model significantly reduced tumor burden, hepatic inflammation, and fibrosis, while improving liver function markers. Histological assessments confirmed alleviation of liver injury, and quantitative polymerase chain reaction analyses revealed decreased expression of proinflammatory cytokines. Collectively, these results highlight this hydrogel platform as a robust strategy to stabilize phenolic drugs, achieve tumor-targeted delivery, and enable controlled release. These findings highlight its potential as an advanced therapeutic approach for HCC and a versatile framework applicable to other polyphenolic agents in oncology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hydrogels: synthesis, properties, applications · Nanoplatforms for cancer theranostics · Hepatocellular Carcinoma Treatment and Prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Hepatocellular carcinoma10.1038/s41572-020-00240-3 ↗
2. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment10.1186/s12967-024-05493-0 ↗
3. Trends in hepatocellular carcinoma mortality rates in the US and projections through 204010.1001/jamanetworkopen.2024.45525 ↗
4. Hepatocellular carcinoma10.1016/S0140-6736(18)30010-2 ↗
5. Imaging to predict prognosis in hepatocellular carcinoma: current and future perspectives10.1148/radiol.221429 ↗
6. Hepatocellular carcinoma10.1056/NEJMra1001683 ↗
7. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update10.1200/JCO.23.02745 ↗
8. Combating drug resistance in hepatocellular carcinoma: no awareness today, no action tomorrow10.1016/j.biopha.2023.115561 ↗
9. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial10.1016/S0140-6736(17)31046-2 ↗
10. Sorafenib in advanced hepatocellular carcinoma10.1056/NEJMoa0708857 ↗
11. Evolving therapeutic landscape of advanced hepatocellular carcinoma10.1038/s41575-022-00704-9 ↗
12. Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers10.1001/jamaoncol.2015.5927 ↗
13. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects10.1038/s41392-020-0187-x ↗
14. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial10.1200/JCO.19.01307 ↗
15. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review10.1186/s11658-021-00301-9 ↗
16. Natural polyphenols in cancer therapy10.3109/10408363.2011.631268 ↗
17. Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy10.1038/s41423-025-01308-4 ↗
18. The immunology of hepatocellular carcinoma10.1038/s41590-018-0044-z ↗
19. Quercetin shows anti‐tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway10.1002/cam4.2388 ↗
20. Apigenin inhibits lipid metabolism of hepatocellular carcinoma cells by targeting the histone demethylase KDM1A10.1016/j.phymed.2024.156024 ↗
21. Protocatechuic acid induces cell death in HepG2 hepatocellular carcinoma cells through a c-Jun N-terminal kinase-dependent mechanism10.1007/s10565-006-0082-4 ↗
22. Quercetin pharmacokinetics in humans, Biopharm10.1002/bdd.605 ↗
23. Does oral apigenin have real potential for a therapeutic effect in the context of human gastrointestinal and other cancers?10.3389/fphar.2021.681477 ↗
24. Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC–tandem mass spectrometry10.1016/j.jchromb.2012.09.032 ↗
25. Hydrodynamic transfection for generation of novel mouse models for liver cancer research10.1016/j.ajpath.2013.12.002 ↗
26. Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis10.1016/j.jhep.2021.12.019 ↗
27. pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy10.1016/j.actbio.2017.06.001 ↗
28. Liquid chromatography–tandem mass spectrometry analysis of protocatechuic aldehyde and its phase I and II metabolites in rat10.1016/j.jchromb.2007.05.042 ↗
29. Enzymatic oxidation of vanillin, isovanillin and protocatechuic aldehyde with freshly prepared Guinea pig liver slices10.1159/000083641 ↗
30. Simultaneous determination and pharmacokinetic study of protocatechuic aldehyde and its major active metabolite protocatechuic acid in rat plasma by liquid chromatography–tandem mass spectrometry10.1093/chromsci/bmv240 ↗
31. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy10.1126/sciadv.adc8738 ↗
32. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer10.1016/j.addr.2023.115083 ↗
33. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis—Mission possible?10.1016/j.addr.2016.07.001 ↗
34. Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer10.1001/jamanetworkopen.2020.7911 ↗
35. EASL clinical practice guidelines on the management of hepatocellular carcinoma10.1016/j.jhep.2024.08.028 ↗
36. IL-6 promotes tumor growth through immune evasion but is dispensable for cachexia10.1038/s44319-024-00144-3 ↗
37. Inflammation and tumor progression: signaling pathways and targeted intervention10.1038/s41392-021-00658-5 ↗
38. Injectable solid hydrogel: mechanism of shear-thinning and immediate recovery of injectable β-hairpin peptide hydrogels10.1039/c0sm00642d ↗
39. Comparative vibration levels perceived among species in a laboratory animal facility
40. Protocatechuic acid as a potent anticarcinogenic compound in purple rice bran against diethylnitrosamine-initiated rat hepatocarcinogenesis10.1038/s41598-022-14888-2 ↗
41. Protocatechuic acid-based supramolecular hydrogel targets SerpinB9 to achieve local chemotherapy for OSCC10.1021/acsami.2c07534 ↗
42. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth10.1016/j.ccell.2023.02.016 ↗
43. Tissue invasion and metastasis: molecular, biological and clinical perspectives10.1016/j.semcancer.2015.03.008 ↗
44. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
45. NIR-activated nanosystems with self-modulated bacteria targeting for enhanced biofilm eradication and caries prevention
46. Structure–reactivity relationships in a small library of imine-type dynamic covalent materials: determination of rate and equilibrium constants enables model prediction and validation of a unique mechanical softening in dynamic hydrogels10.1021/jacs.4c08099 ↗
47. Nanoarchitectonics of injectable biomimetic conjugates for cartilage protection and therapy based on degenerative osteoarthritis progression10.34133/bmr.0075 ↗
48. Factors influencing the drug release from calcium phosphate cements
49. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems10.1517/17425241003602259 ↗
50. Surface charge switchable and pH-responsive chitosan/polymer core-shell composite nanoparticles for drug delivery application10.1016/j.compositesb.2017.03.028 ↗
51. Design and development of pH-responsive polyurethane membranes for intravaginal release of nanomedicines10.1016/j.actbio.2018.10.003 ↗
52. pH-responsive water-soluble polymer carriers for cell-selective metabolic sialylation labeling10.1021/acs.analchem.1c03261 ↗
53. Self-assembly of alkynylplatinum(II) complexes for sialic acid detection and differentiation of cancer cells from normal cells10.1021/jacs.5c03210 ↗
54. Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS10.1016/j.talanta.2024.126056 ↗
55. Phenylboronic acid-functionalized biomaterials for improved cancer immunotherapy via sialic acid targeting10.1016/j.cis.2024.103301 ↗
56. Structural control of boronic acid ligands enhances intratumoral targeting of sialic acid to eradicate cancer stem-like cells10.1021/acsabm.0c00530 ↗
57. Acidity generated by the tumor microenvironment drives local invasion10.1158/0008-5472.CAN-12-2796 ↗
58. Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer10.1038/s12276-024-01180-8 ↗
59. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential10.1038/s41392-020-00311-7 ↗
60. Anticoagulatory, antiinflammatory, and antioxidative effects of protocatechuic acid in diabetic mice10.1021/jf9015202 ↗
61. NF-κB in inflammation and cancer10.1038/s41423-025-01310-w ↗
62. NF-κB signaling in inflammation10.1038/sigtrans.2017.23 ↗
63. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma10.1038/nrgastro.2010.213 ↗